<?xml version="1.0" encoding="UTF-8"?>
<p>We next tested whether vaccination with AdV-260 and AdV-451 could improve survival in a lethal CHIKV mouse model. Mice lacking the type I IFN receptor (
 <italic>Ifnar1</italic>
 <sup>−/−</sup>
 <italic>)</italic> are extremely susceptible to CHIKV and succumb to virus infection 3-4 dpi (
 <xref rid="B40" ref-type="bibr">40</xref>), and represent a highly stringent survival model. Mice receiving AdV-260 and AdV-451 exhibited a 1-day advantage in survival over the AdV-Control group (
 <xref ref-type="fig" rid="F8">Figures 8E,F</xref>). Therefore, the CD8
 <sup>+</sup> T cell vaccine could protect immunocompetent mice from footpad swelling after CHIKV f.p. challenge, and the vaccine provided significant survival advantage in 
 <italic>Ifnar1</italic>
 <sup>−/−</sup> mice.
</p>
